Prasterone - Paladin
Alternative Names: Dehydroepiandrosterone - Paladin; DHEA - Paladin; FidelinLatest Information Update: 28 Feb 2011
At a glance
- Originator Beckman Research Institute
- Developer Paladin Labs
- Class Androstenols; Anti-inflammatories; Hormonal replacements; Small molecules
- Mechanism of Action Dehydroepiandrosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Adrenal insufficiency; Alzheimer's disease; Andropause
Most Recent Events
- 10 Jul 2006 No development reported - Clinical-Phase-Unknown for Andropause in Canada (unspecified route)
- 10 Jul 2006 Phase-II clinical trials in Adrenal insufficiency in Canada (unspecified route)
- 07 Jul 2004 Paladin intends to partner funding, development and commercialisation of prasterone in Europe, the US and Japan (http://www.paladinlabs.com)